MedRhythms’ core product is a digital therapy platform that combines sensors, music and software to deliver an evidence‑based intervention called rhythmic auditory stimulation to improve gait after neurologic injury. The platform leverages musical entrainment to engage auditory‑motor brain circuitry and promote neuroplasticity. Its lead digital therapeutic received Breakthrough Device designation from the U.S. FDA to treat chronic walking deficits from stroke. The company is preparing an FDA submission to enable a commercial launch and plans to begin clinical trials. MedRhythms is also expanding its treatment pipeline to explore music‑based therapies for Parkinson’s, acute stroke and multiple sclerosis and is participating in a neuroimaging study with Massachusetts General Hospital. Financially, the company has raised $31 million to date following the recent Series B. MedRhythms develops a patent-pending digital therapeutics platform that combines sensors, AI, and music to deliver evidence-based, prescription products aimed at improving and measuring walking in people with neurologic injuries and diseases. The company’s first product targets the post-stroke population, and its pipeline includes therapies for Parkinson’s Disease, Multiple Sclerosis, Aging‑In‑Place, and Traumatic Brain Injury. MedRhythms intends to pursue FDA approval for its prescription digital therapeutics and to build algorithms for personalized therapeutics addressing movement, language, and cognition deficits. The platform also collects data the company says can be used for early disease detection, tracking progression, and predicting adverse events. Following the financing, MedRhythms plans to hire software, product, and commercial staff for its Portland, ME office. The company began as a therapy services business that launched out of Spaulding Rehabilitation Hospital.

Total raised

$30M

Funding rounds

2

Latest round

Series B

Latest activity

Jul 2021